Etirinotecan pegol: Completed Phase III enrollment

Nektar completed enrollment of about 840 patients previously treated with cytotoxic chemotherapy regimens in the open-label, international Phase III BEACON trial comparing 145 mg/m 2 IV etirinotecan p...